Giant Biogene Holding Co Ltd
HKEX:2367
Intrinsic Value
Giant Biogene Holding Co. Ltd. engages in providing bioactive material-based beauty and health products. [ Read More ]
The intrinsic value of one Giant Biogene Holding Co Ltd stock under the Base Case scenario is 46.48 HKD. Compared to the current market price of 50.25 HKD, Giant Biogene Holding Co Ltd is Overvalued by 8%.
Valuation Backtest
Giant Biogene Holding Co Ltd
Run backtest to discover the historical profit from buying and selling Giant Biogene Holding Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Giant Biogene Holding Co Ltd
| Current Assets | 4.1B |
| Cash & Short-Term Investments | 3.8B |
| Receivables | 102m |
| Other Current Assets | 254.3m |
| Non-Current Assets | 838m |
| PP&E | 711.6m |
| Intangibles | 7.4m |
| Other Non-Current Assets | 119m |
| Current Liabilities | 530.6m |
| Accounts Payable | 133.1m |
| Other Current Liabilities | 397.5m |
| Non-Current Liabilities | 80.3m |
| Long-Term Debt | 1.2m |
| Other Non-Current Liabilities | 79.2m |
Earnings Waterfall
Giant Biogene Holding Co Ltd
|
Revenue
|
3.5B
CNY
|
|
Cost of Revenue
|
-577m
CNY
|
|
Gross Profit
|
2.9B
CNY
|
|
Operating Expenses
|
-1.2B
CNY
|
|
Operating Income
|
1.7B
CNY
|
|
Other Expenses
|
-263.4m
CNY
|
|
Net Income
|
1.5B
CNY
|
Free Cash Flow Analysis
Giant Biogene Holding Co Ltd
Profitability Score
Profitability Due Diligence
Giant Biogene Holding Co Ltd's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
Score
Giant Biogene Holding Co Ltd's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Giant Biogene Holding Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Giant Biogene Holding Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Giant Biogene Holding Co Ltd
According to Wall Street analysts, the average 1-year price target for Giant Biogene Holding Co Ltd is 54.55 HKD with a low forecast of 43.43 HKD and a high forecast of 66.13 HKD.
Shareholder Return
Price
Giant Biogene Holding Co Ltd
| Average Annual Return | 30.15% |
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -50% |
| Market Capitalization | 50B HKD |
| Shares Outstanding | 995 000 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Giant Biogene Holding Co. Ltd. engages in providing bioactive material-based beauty and health products. The company is headquartered in Xi'An, Shaanxi. The company went IPO on 2022-11-04. The firm is principally engaged the research, development, manufacture and sale of bioactive material-based beauty and health products through its subsidiaries. The firm's main products include functional skincare products and medical dressings, and they are produced with recombinant collagen as the key bioactive ingredient. The firm also develops and manufactures rare ginsenosides technology-based functional foods. The firm mainly conducts its businesses within the domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one Giant Biogene Holding Co Ltd stock under the Base Case scenario is 46.48 HKD.
Compared to the current market price of 50.25 HKD, Giant Biogene Holding Co Ltd is Overvalued by 8%.
You don't have any saved screeners yet
